As more and more integrated delivery networks embrace value-based care, the pharmaceutical companies they contract with for prescription drugs also are pivoting away from pricing models that tie sales revenue to volume.

While the transition won’t be easy, value-based drug contracting will be more manageable in certain parts of the country due to factors ranging from the prevalence of large physician groups to ACO penetration.

Download our infographic, Top 5 States for Value-Based Contracting, to learn which states hold the best opportunities for pharmaceutical manufacturers.








How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now